● Recruiting

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Condition: Neuroblastoma · Sponsor: New Approaches to Neuroblastoma Therapy Consortium

PhasePhase 2

Planned participants62

Who can joinAll sexes, 1 Year to 31 Years

Healthy volunteersNo

About this study

This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.

This description comes directly from the study's public registry record.

Talk to the study team

Araz Marachelian, MD · 3233615687 · nantops@chla.usc.edu

Always discuss trial participation with your own doctor first.

Locations (13)

Children's Hospital Los Angeles	Los Angeles, California, United States	Recruiting
UCSF Benioff Children's Hospital	San Francisco, California, United States	Recruiting
Children's Hospital Colorado	Aurora, Colorado, United States	Recruiting
Comer Children's Hospital, University of Chicago	Chicago, Illinois, United States	Not Yet Recruiting
Boston Children's Hospital, Dana-Farber Cancer Institute.	Boston, Massachusetts, United States	Not Yet Recruiting
C.S Mott Children's Hospital	Ann Arbor, Michigan, United States	Not Yet Recruiting
Cincinnati Children's Hospital Medical Center	Cincinnati, Ohio, United States	Not Yet Recruiting
Nationwide Children's Hospital	Columbus, Ohio, United States	Recruiting
Children's Hospital of Philadelphia	Philadelphia, Pennsylvania, United States	Recruiting
St. Jude Children's Research Hospital	Memphis, Tennessee, United States	Recruiting
University of Texas Southwestern	Dallas, Texas, United States	Recruiting
Cook Children's Medical Center	Fort Worth, Texas, United States	Recruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06450041